Cardiol Therapeutics Inc Class A (CRDL) - Total Liabilities

Latest as of December 2025: CA$5.74 Million CAD ≈ $4.15 Million USD

Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has total liabilities worth CA$5.74 Million CAD (≈ $4.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CRDL net asset momentum to track the company's year-over-year net asset growth rate.

Cardiol Therapeutics Inc Class A - Total Liabilities Trend (2017–2025)

This chart illustrates how Cardiol Therapeutics Inc Class A's total liabilities have evolved over time, based on quarterly financial data.

Cardiol Therapeutics Inc Class A Competitors by Total Liabilities

The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their total liabilities.

Company	Country	Total Liabilities
FENIX Resources Ltd AU:FEX	Australia	AU$186.70 Million
Tonix Pharmaceuticals Holding Corp NASDAQ:TNXP	USA	$32.02 Million
Domo Inc NASDAQ:DOMO	USA	$393.54 Million
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret IS:ATATP	Turkey	TL633.82 Million
Welldone Co TWO:6170	Taiwan	NT$3.30 Billion
Asara Resources Ltd AU:AS1	Australia	AU$346.57K
SAI SILKS (KALAMANDIR) LIMITED NSE:KALAMANDIR	India	Rs5.88 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Cardiol Therapeutics Inc Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cardiol Therapeutics Inc Class A market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.16	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	3.79	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cardiol Therapeutics Inc Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cardiol Therapeutics Inc Class A (2017–2025)

The table below shows the annual total liabilities of Cardiol Therapeutics Inc Class A from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	CA$5.74 Million ≈ $4.15 Million	-19.52%
2024-12-31	CA$7.14 Million ≈ $5.16 Million	-15.60%
2023-12-31	CA$8.45 Million ≈ $6.12 Million	-13.97%
2022-12-31	CA$9.83 Million ≈ $7.11 Million	-15.56%
2021-12-31	CA$11.64 Million ≈ $8.42 Million	+343.72%
2020-12-31	CA$2.62 Million ≈ $1.90 Million	+215.69%
2019-12-31	CA$830.83K ≈ $601.01K	-65.53%
2018-12-31	CA$2.41 Million ≈ $1.74 Million	+557.28%
2017-12-31	CA$366.76K ≈ $265.31K	--

About Cardiol Therapeutics Inc Class A

TO:CRDL Canada Drug Manufacturers - Specialty & Generic

Market Cap

$142.19 Million

CA$196.56 Million CAD

Market Cap Rank

#17794 Global

#572 in Canada

Share Price

CA$1.76

Change (1 day)

+2.92%

52-Week Range

CA$1.28 - CA$2.23

All Time High

CA$8.13